Grant: Operating Grant
McMaster University
$217,882.00
A randomized controlled trial of oseltamivir in outpatients with chronic pulmonary disease: a pilot study
EF 2013-14
Résumé
Patients with chronic disease are at high risk for complications of influenza, including hospitalization, pneumonia, bronchitis, and reduced functional status. Antiviral medications, such as oseltamivir, can be used to treat influenza. However, it is uncertain whether oseltamivir can reduce serious complications in those at high risk for complications. In a pilot study, we
propose to assess if it is feasible to randomize patients with chronic lung disease and acute respiratory infection during influenza season to either early treatment with oseltamivir versus placebo. We will assess hospitalization as well as other outcomes such as lower respiratory tract infection, pneumonia, sinusitis, antimicrobial prescriptions, visits to medical
providers, changes in functional status, health related quality of life, absenteeism from work, additional care or support needed in the home, and duration of illness.
Programme
Operating Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
306099
Name
Loeb Mark B
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Randomized Controlled Trials
Projecttitle
A randomized controlled trial of oseltamivir in outpatients with chronic pulmonary disease: a pilot study
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$217,882
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Clinical Trial; Influenza; Oseltamivir; Respiratory Illness
Abstract
Patients with chronic disease are at high risk for complications of influenza, including hospitalization, pneumonia, bronchitis, and reduced functional status. Antiviral medications, such as oseltamivir, can be used to treat influenza. However, it is uncertain whether oseltamivir can reduce serious complications in those at high risk for complications. In a pilot study, we
propose to assess if it is feasible to randomize patients with chronic lung disease and acute respiratory infection during influenza season to either early treatment with oseltamivir versus placebo. We will assess hospitalization as well as other outcomes such as lower respiratory tract infection, pneumonia, sinusitis, antimicrobial prescriptions, visits to medical
providers, changes in functional status, health related quality of life, absenteeism from work, additional care or support needed in the home, and duration of illness.
Competitiondate
201403
Approvedterm2
1 yr 0 mth
Pinamesdelim
Loeb, Mark B
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $217,882~ $0~